11 January 2021 - The initial agenda was revised within 24 hours of publication on the PBS website.

Without notice, the agenda for the next scheduled PBAC has been revised.

Two changes were made:

• The addition of a minor submission for avelumab (Bavencio) for patients with renal cell carcinoma
  
• The closing date for consumer comments has been extended to 10 February 2021
  

Read PBAC agenda